Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Gross Margin (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Gross Margin data on record, last reported at 92.8% in Q4 2025.

  • For Q4 2025, Gross Margin rose 21.0% year-over-year to 92.8%; the TTM value through Dec 2025 reached 93.2%, up 21.0%, while the annual FY2025 figure was 93.2%, 21.0% up from the prior year.
  • Gross Margin reached 92.8% in Q4 2025 per TARS's latest filing, roughly flat from 93.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 107.1% in Q4 2021 and bottomed at 79.85% in Q3 2023.
  • Average Gross Margin over 5 years is 94.29%, with a median of 93.9% recorded in 2025.
  • Peak YoY movement for Gross Margin: crashed -1110bps in 2022, then soared 1341bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 107.1% in 2021, then dropped by -10bps to 96.0% in 2022, then decreased by -6bps to 90.7% in 2023, then rose by 2bps to 92.58% in 2024, then increased by 0bps to 92.8% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 92.8% in Q4 2025, 93.0% in Q3 2025, and 93.92% in Q2 2025.